Science

Science

Leveraging cutting-edge science and technology to identify and propel best-in-class biologics to the clinic.

Paragon employs a breadth of protein engineering technologies to perform biologics discovery and optimization. We have built a team of exceptional leaders in drug discovery and development who work with top-tier partners to develop transformative programs.

Science

We engineer the best drug candidates by applying high-throughput screening systems and optimization techniques.

Science

Our CMC model enables us to rapidly and reliably progress novel treatments from ideation to the clinic.

Science

Our development process allows us to successfully execute highly efficient program timelines with cutting-edge technologies while ensuring quality is never sacrificed.

Pipeline

Fueling a pipeline of best-in-class therapies for a range of diseases.

Our business model centers on bringing therapies to patients as rapidly as possible—once a program or set of programs achieves significant progress, we enable their advancement to the clinic by launching spinout companies, engaging in partnerships with other biopharma companies, or continuing to shape their development in-house at Paragon. Our product pipeline demonstrates our progress, with the leading program in clinical trials less than two years from ideation.

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR004 (APG777)

Clinical

PR001 (APG808)

Ind-Enabling

PR007 (APG990)

Discovery

PR012 (APG222)

Discovery

Rights/Partner

Apogee

Apogee Therapeutics is the first company to spin out of Paragon in 2022. Apogee is advancing a pipeline of potentially best-in-class product candidates targeting clinically validated biology and well-established development pathways to address the needs of the millions of people living with immunological and inflammatory disorders.

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR011 (SPY001)

Ind-Enabling

PR010 (SPY002)

Ind-Enabling

PR014 (SPY003)

Discovery

PR015 (SPY004)

Discovery

PR026 (SPY130)

Ind-Enabling

PR022 (SPY120)

Discovery

PR025 (SPY230)

Ind-Enabling

Rights/Partner

Spyre Logo

Spyre Therapeutics is the second company formed around technology spun out of Paragon. Established in 2023, Spyre is advancing a pipeline of product candidates that maximize the efficacy, safety, and convenience of treatments for inflammatory bowel disease (IBD), combining best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to potentially transform the treatment paradigm.

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR035 (ORKA001)

Discovery

PR029 (ORKA002)

Discovery

Rights/Partner

Oruka Logo

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR002

Ind-Enabling

PR013

Discovery

Rights/Partner

Undisclosed

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

Multiple internal programs

Discovery

Discovery

Discovery

Rights/Partner

Paragon

Spinouts

Building successful companies to accelerate therapeutic impact.

We are committed to improving the patient experience through innovation. Our scientific approach and expertise have provided the foundation for several spinout companies devoted to bringing best-in-class treatments to patients living with chronic conditions.

Apogee Logo

ABOUT APOGEE THERAPEUTICS

Apogee Therapeutics is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Apogee is building a pipeline of product candidates targeting clinically validated biology and well-established development pathways. Based in San Francisco, CA, Apogee was founded in 2022 by Fairmount and Venrock Healthcare Capital Partners and is backed by leading healthcare investors. Visit their website for more details.

Spyre Logo

ABOUT SPYRE THERAPEUTICS

Spyre Therapeutics is a biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD. The company was founded in 2023 by Fairmount and is based in Waltham, MA. Visit their website for more details.

Team

Dedicated experts with a passion for improving health outcomes.

Paragon is led by a collaborative team of innovators with deep expertise in biologics engineering and development. Our collaboration with FairJourney Biologics expands the reach and capabilities of our team through dedicated antibody discovery experts and resources. Together, we are motivated to tackle some of the toughest disease areas and improve quality of life for patients.

Evan Thompson Headshot

Evan Thompson, Ph.D.

CHIEF OPERATING OFFICER

View Bio
Hussam Shaheen Headshot

Hussam Shaheen, Ph.D.

HEAD OF RESEARCH

View Bio
Keri Lantz Headshot

Keri Lantz

HEAD OF FINANCE

View Bio
Damon Banks Headshot

Damon Banks, Ph.D., J.D.

HEAD OF LEGAL

View Bio
Jason Oh Headshot

Jason Oh, Ph.D.

SENIOR VICE PRESIDENT OF BIOLOGY

View Bio
Shawn Russell Headshot

Shawn Russell, Ph.D.

SENIOR VICE PRESIDENT OF CMC

View Bio
Neta Batscha Headshot

Neta Batscha

SENIOR VICE PRESIDENT OF CORPORATE STRATEGY & OPERATIONS

View Bio
Mike Meehl Headshot

Michael Meehl, Ph.D.

SENIOR VICE PRESIDENT OF BIOLOGICAL RESEARCH

View Bio
Petros Psathas Headshot

Petros Psathas, Ph.D.

VICE PRESIDENT OF PRECLINICAL DEVELOPMENT

View Bio
Cyrus Stacey Headshot

Cyrus Stacey

VICE PRESIDENT OF QUALITY

View Bio
Archit Sheth-Shah Headshot

Archit Sheth-Shah

SENIOR DIRECTOR OF PORTFOLIO STRATEGY

View Bio
Eric Zhu Headshot

Eric Zhu, Ph.D.

SENIOR DIRECTOR OF BIOTHERAPEUTICS DISCOVERY

View Bio
Byron Kwan Headshot

Byron Kwan, Ph.D.

DIRECTOR OF BIOTHERAPEUTICS

View Bio
Daniel Rios Headshot

Daniel Rios, Ph.D.

DIRECTOR OF BIOLOGY

View Bio
Yuqi Liu Headshot

Yuqi Liu, Ph.D.

DIRECTOR OF PROTEIN SCIENCE

View Bio
Andrew Schirmer Headshot

Andrew Schirmer

Associate Director of Manufacturing

View Bio
M. Murshid AlamAlam Headshot

M. Murshid Alam, Ph.D.

PRINCIPAL SCIENTIST

View Bio
Byong Ha Kang Headshot

Byong Ha Kang, Ph.D.

PRINCIPAL SCIENTIST

View Bio
Jake Milligan Headshot

Jake Milligan, Ph.D.

PRINCIPAL SCIENTIST

View Bio
Kevin Kramer Headshot

Kevin Kramer, Ph.D.

Senior Scientist

View Bio
Rita Vaz Headshot

Rita Vaz, Ph.D.

DIRECTOR OF PROGRAM AND ALLIANCE MANAGEMENT

View Bio
Soraia Oliveira Headshot

Soraia Oliveira, Ph.D.

Senior Project Manager for Antibody Discovery and Development

View Bio
Joana Ministro Headshot

Joana Ministro, Ph.D.

PROJECT MANAGER FOR ANTIBODY DISCOVERY AND DEVELOPMENT

View Bio
Joana Vidal Silva Headshot

Joana Vidal Silva

PROJECT MANAGER FOR ANTIBODY DISCOVERY & DEVELOPMENT

View Bio
katie Kelley Headshot

Katie Kelley

SENIOR CONTROLLER

View Bio
Melissa Donnarummo Headshot

Melissa Donnarummo

Director of Project Accounting

View Bio
Stefanie Feldman Headshot

Stefanie (Stef) Feldmann

DIRECTOR OF BUSINESS OPERATIONS

View Bio
Lauren Gillis Headshot

Lauren Gillis

DIRECTOR OF EXECUTIVE ADMINSTRATION

View Bio
James Nzukie Headshot

James Nzukie

DIRECTOR OF FINANCE PLANNING & ANALYSIS

View Bio
Sophia Medina Headshot

Sophia Medina

ADMINISTRATIVE ASSISTANT

View Bio
About usAbout us
Fairmount

About Us

Paragon was founded by Fairmount in 2021 as the firm’s discovery engine for best-in-class biologics. Leveraging a dedicated in-house team of scientific experts in antibody development, as well as our partnership with FairJourney Biologics, Paragon pursues unique therapeutic concepts and enables their rapid proof-of-concept validation. Fairmount is dedicated to investing in promising new therapies developed by biotechnology and life science companies and works closely with the Paragon team to provide research and strategic direction.

News

The latest Paragon news and developments.

Arrow
Arrow
Join Us

Join Us

Be a part of our innovative team.

We are excited about the future as we advance our state-of-the-art science. Come join our team and help us shape the next generation of biologic treatments.

VIEW POSITIONS ON LINKEDIN

Contact

For media inquiries or more information: